JP2015535256A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535256A5
JP2015535256A5 JP2015539867A JP2015539867A JP2015535256A5 JP 2015535256 A5 JP2015535256 A5 JP 2015535256A5 JP 2015539867 A JP2015539867 A JP 2015539867A JP 2015539867 A JP2015539867 A JP 2015539867A JP 2015535256 A5 JP2015535256 A5 JP 2015535256A5
Authority
JP
Japan
Prior art keywords
syndrome
usher
compound
pharmaceutically acceptable
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015539867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535256A (ja
JP6290910B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066938 external-priority patent/WO2014066835A1/en
Publication of JP2015535256A publication Critical patent/JP2015535256A/ja
Publication of JP2015535256A5 publication Critical patent/JP2015535256A5/ja
Application granted granted Critical
Publication of JP6290910B2 publication Critical patent/JP6290910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015539867A 2012-10-25 2013-10-25 ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 Active JP6290910B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718593P 2012-10-25 2012-10-25
US61/718,593 2012-10-25
US201361775376P 2013-03-08 2013-03-08
US61/775,376 2013-03-08
PCT/US2013/066938 WO2014066835A1 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Publications (3)

Publication Number Publication Date
JP2015535256A JP2015535256A (ja) 2015-12-10
JP2015535256A5 true JP2015535256A5 (enExample) 2016-12-08
JP6290910B2 JP6290910B2 (ja) 2018-03-07

Family

ID=50545355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539867A Active JP6290910B2 (ja) 2012-10-25 2013-10-25 ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法

Country Status (10)

Country Link
EP (1) EP2912038B1 (enExample)
JP (1) JP6290910B2 (enExample)
AU (1) AU2013334138B2 (enExample)
CA (1) CA2889537C (enExample)
ES (1) ES2693166T3 (enExample)
IL (1) IL238287B (enExample)
PL (1) PL2912038T3 (enExample)
TR (1) TR201816028T4 (enExample)
WO (1) WO2014066835A1 (enExample)
ZA (1) ZA201502654B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902293B2 (ja) 2011-04-25 2016-04-13 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
CA2889494C (en) * 2012-10-25 2018-12-18 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EP4178580B1 (en) 2020-07-09 2025-11-05 Usher III Initiative, Inc. Bf 844 for use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295550A3 (en) * 2001-04-30 2011-12-14 Vertex Pharmaceuticals Incorporated Crystal structures of GSK-3beta protein and protein complexes and their use
ATE554087T1 (de) * 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
AU2009262068C1 (en) * 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
JP5902293B2 (ja) * 2011-04-25 2016-04-13 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
CA2889494C (en) * 2012-10-25 2018-12-18 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Similar Documents

Publication Publication Date Title
JP2015535257A5 (enExample)
JP2017186358A5 (enExample)
JP2014507446A5 (enExample)
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2013014622A5 (enExample)
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
JP2016518337A5 (enExample)
JP2014221779A5 (enExample)
JP2016515561A5 (enExample)
EP4227304A3 (en) Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons
JP2013525444A5 (enExample)
JP2016515522A5 (enExample)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2013518107A5 (enExample)
WO2014178931A8 (en) Sobetirome in the treatment of myelination diseases
MX343620B (es) Forma polimorfica de clorhidrato de pridopidina.
HK1219943A1 (zh) 用於治疗眼科疾病和障害的取代3-苯基丙胺衍生物
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
JP2013522326A5 (enExample)
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
EA201891018A1 (ru) Липиды и липидные композиции для доставки активных агентов
JP2013523846A5 (enExample)
JP2014503593A5 (enExample)
HK1217092A1 (zh) 治疗性化合物及其用途